Repligen Earnings Call Highlights Growth, Margin Momentum

Repligen ((RGEN)) has held its Q1 earnings call. Read on for the main highlights of the call.

Repligen’s latest earnings call carried an upbeat tone, as management highlighted double-digit revenue growth, improving margins, and stronger cash generation. While acknowledging some timing-related headwinds and portfolio pruning that trim reported sales, executives emphasized that demand is broadening, profitability is rising, and strategic initiatives are laying the groundwork for durable growth through 2027 and beyond.

Strong Q1 Revenue and Organic Growth

Repligen opened 2026 with Q1 revenue of $194M, up 15% year over year on a reported basis and 11% organically after excluding FX and acquisitions. Currency provided roughly a 3‑point tailwind, and an upstream Analytics acquisition contributed two months of inorganic revenue, underscoring that the core business is expanding at a solid double-digit clip.

Margin Expansion and Profitability

Profitability moved sharply higher, with adjusted gross profit reaching $108M and gross margin improving 180 basis points to 55.5%. Adjusted operating income climbed 28% to $30M, lifting operating margin to 15.4%, while adjusted EBITDA hit $40M, translating to an approximately 21% margin as cost discipline and better mix flowed through the P&L.

Earnings, Cash and EPS Upside

Bottom line performance outpaced sales, as adjusted net income rose 22% to $27M and adjusted diluted EPS increased to $0.48 from $0.39 a year earlier, a 23% gain. The balance sheet remained a key strength with $785M in cash and marketable securities, up $17M sequentially, supported by $20M of operating cash flow against a modest $5M of capital spending.

Raised Full-Year EPS Guidance and Revenue Range

Management paired the strong quarter with higher full‑year guidance, now calling for $803M–$833M in 2026 revenue, or 9%–13% growth both reported and organic. Adjusted operating income is guided to $124M–$132M and adjusted EPS to $1.97–$2.05, about 18% growth at the midpoint versus last year and $0.04 above the prior outlook despite the small revenue headwind from a divestiture.

Franchise Strength — Analytics, Chromatography, Proteins

Key technology franchises are driving the story, with Analytics revenue surging more than 50% in Q1 and targeted for above 20% annual growth by 2026 as adoption accelerates. Chromatography rose more than 25% in the quarter and is also expected to exceed 20% growth through 2026, while the Proteins business delivered mid‑teens expansion with at least low‑double‑digit growth expected this year.

Broad End-Market and Geographic Performance

Growth was broad based, as contract development and manufacturing customers posted mid‑teens gains and biopharma demand improved despite tough comparisons, while emerging biotechs grew more than 20%. Regionally, North America accounted for about 46% of sales, EMEA 37%, and APAC 17%, with Asia Pacific up more than 25% and China nearly doubling sequentially for its strongest quarter in over two years.

Strategic Actions — Transformation Office and China Partnership

Repligen unveiled a transformation office aimed at upgrading operations, IT, and AI capabilities, targeting at least one percentage point of annualized margin uplift by the end of 2027. In China, the company signed a multi‑phase OEM partnership to expand local manufacturing and better “localize” its presence, with the collaboration slated to begin ramping production in 2027 to counter intensifying competition.

Portfolio and Products — Consumables, Services, ATF Positioning

The company’s consumables portfolio, including proteins, continued to grow at a double‑digit pace, supported by rising adoption of single‑use technologies. Services revenue grew roughly 30%, and management reiterated Repligen’s leadership in ATF and process intensification, signaling that after a period of softer demand, ATF should return to strong growth in 2027 alongside a pipeline of new product launches.

Polymem Divestiture Reduced Revenue

Portfolio reshaping weighed modestly on the top line as Repligen completed the sale of its noncore Polymem business in France, removing about $7M of annual revenue. However, Polymem had been generating an adjusted operating loss, so the divestiture is expected to enhance the company’s margin profile even as it slightly trims reported revenue guidance.

ATF and Gene Therapy Headwinds/Timing

Short‑term headwinds are most visible around ATF and newer modalities, where customer‑specific timing issues and a slowdown in some gene therapy programs are dampening Filtration and ATF growth in 2026. Management framed these pressures as transitory, reiterating expectations that ATF will shift back to being a meaningful growth tailwind starting in 2027 as projects progress.

Timing-Related Margin Normalization Risk

Investors were cautioned that some Q1 margin benefits reflect timing rather than structural change, particularly favorable cost absorption from production patterns that will not repeat. The company expects gross margin in Q2 to run slightly below the full‑year range, with Q3 likely to be the lowest‑margin quarter before metrics trend back toward the guided averages.

Customer Decision and Capital Equipment Uncertainty

Management also pointed to ongoing uncertainty around capital equipment, where order timing and revenue recognition depend on the pace of customer site readiness and decision‑making. While signs of recovery in larger projects are encouraging, the company expects demand to remain somewhat lumpy, with deal flow tied closely to customers’ internal approval and installation schedules.

Incremental One-Time Costs and External Headwinds

The new transformation office carries projected nonrecurring charges of roughly $5M–$6M through 2027, which will be excluded from adjusted results but still represent a near‑term cash and accounting headwind. Guidance also factors in a couple of million dollars of tariff surcharges and assumes only limited disruption from broader geopolitical tensions, indicating management has stress‑tested its outlook against external risks.

Emerging Biotech Still Below Historical Levels

While emerging biotech revenue grew more than 20% in Q1, management noted that activity in this customer group remains below pre‑downturn levels and accounted for only about 8%–9% of sales. The recovery trajectory in that segment is encouraging but incomplete, suggesting further upside if funding conditions and program starts in early‑stage biotech continue to normalize.

Increased Local Competition in China Requires Localization

In China, Repligen faces intensifying competition from local players, pushing the company to strengthen its on‑the‑ground presence rather than operate from afar. The OEM partnership is designed to make the company appear more local and responsive, but leadership stressed that the benefits will build gradually from 2027 onward and that the competitive environment will remain challenging.

Forward-Looking Guidance and Outlook

Looking ahead, Repligen reaffirmed its 2026 revenue outlook of $803M–$833M with 9%–13% growth and 110–160 basis points of gross‑margin expansion, alongside $124M–$132M in adjusted operating income and EPS of $1.97–$2.05. Management expects Q2 organic growth similar to Q1, margin seasonality with Q3 as the trough, CapEx around 3%–4% of revenue, and at least a one‑point margin benefit from transformation initiatives by 2027.

Repligen’s call painted the picture of a company exiting a downcycle with renewed momentum, supported by strong franchises, healthy cash reserves, and higher earnings guidance. Near‑term noise from ATF timing, divestitures, and one‑off costs appears manageable, leaving investors focused on execution of strategic initiatives, geographic expansion, and margin improvement that could underpin attractive multi‑year returns.